References
- Breglio AM, Rusheen AE, Shide ED, et al. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun. 2017 Nov 21;8(1):1654.
- Brock PR, Maibach R, Childs M, et al. Sodium Thiosulfate for protection from Cisplatin-Induced hearing loss. N Engl J Med. 2018 Jun 21;378(25):2376–2385.
- Kim SJ, Park C, Han AL, et al. Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells. Hear Res. 2009 May;251(1–2):70–82.
- Park HJ, Kim MJ, Rothenberger C, et al. GSTA4 mediates reduction of cisplatin ototoxicity in female mice. Nat Commun. 2019 Sep 12;10(1):4150.
- Tang Q, Wang X, Jin H, et al. Cisplatin-induced ototoxicity: updates on molecular mechanisms and otoprotective strategies. Eur J Pharm Biopharm. 2021 Jun;163:60–71.
- Hoshino T, Tabuchi K, Nishimura B, et al. Protective role of Nrf2 in age-related hearing loss and gentamicin ototoxicity. Biochem Biophys Res Commun. 2011 Nov 11;415(1):94–98.
- Zhang W, Xiong H, Pang J, et al. Nrf2 activation protects auditory hair cells from cisplatin-induced ototoxicity independent on mitochondrial ROS production. Toxicol Lett. 2020 Oct 1;331:1–10.
- Mirzaei S, Mohammadi AT, Gholami MH, et al. Nrf2 signaling pathway in cisplatin chemotherapy: potential involvement in organ protection and chemoresistance. Pharmacol Res. 2021 May;167:105575.
- So HS, Kim HJ, Lee JH, et al. Flunarizine induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection of auditory cells from cisplatin. Cell Death Differ. 2006 Oct;13(10):1763–1775.
- Jo ER, Youn CK, Jun Y, et al. The protective role of ferulic acid against cisplatin-induced ototoxicity. Int J Pediatr Otorhinolaryngol. 2019 May;120:30–35.
- Oishi T, Matsumaru D, Ota N, et al. Activation of the NRF2 pathway in Keap1-knockdown mice attenuates progression of age-related hearing loss. NPJ Aging Mech Dis. 2020 Dec 14;6(1):14.
- Delhez A, Lefebvre P, Pequeux C, et al. Auditory function and dysfunction: estrogen makes a difference. Cell Mol Life Sci. 2020 Feb;77(4):619–635.
- Ishii T, Warabi E. Mechanism of rapid nuclear factor-E2-related factor 2 (Nrf2) activation via membrane-associated estrogen receptors: roles of NADPH oxidase 1, Neutral Sphingomyelinase 2 and Epidermal Growth Factor Receptor (EGFR). Antioxidants (Basel). 2019 Mar 18;8(3).
- Nakamagoe M, Tabuchi K, Uemaetomari I, et al. Estradiol protects the cochlea against gentamicin ototoxicity through inhibition of the JNK pathway. Hear Res. 2010 Mar;261(1–2):67–74.
- Hu XJ, Li FF, Wang Y, et al. Effects of cisplatin on the auditory function of ovariectomized rats with estrogen deficiency. Acta Otolaryngol. 2017 Jun;137(6):606–610.
- Van de Water T, Ruben RJ. Growth of the inner ear in organ culture. Ann Otol Rhinol Laryngol. 1974 Sep-Oct;83(5 Pt 2 Suppl 14):1–16.
- Sobkowicz HM, Loftus JM, Slapnick SM. Tissue culture of the organ of Corti. Acta Otolaryngol Suppl. 1993;502:3–36.
- Le Q, Tabuchi K, Hara A. Ceramide-1-phosphate protection of cochlear hair cells against cisplatin ototoxicity. Toxicol Rep. 2016;3:450–457.
- Hall MD, Telma KA, Chang KE, et al. Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res. 2014 Jul 15;74(14):3913–3922.
- Tabuchi K, Pak K, Chavez E, et al. Role of inhibitor of apoptosis protein in gentamicin-induced cochlear hair cell damage. Neuroscience. 2007 Oct 12;149(1):213–222.
- Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013 Mar;48(3):452–458.
- Tani K, Tabuchi K, Hara A. Hair cell loss induced by Sphingosine and a Sphingosine Kinase Inhibitor in the Rat Cochlea. Neurotox Res. 2016 Jan;29(1):35–46.
- Paciello F, Fetoni AR, Mezzogori D, et al. The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity. Sci Rep. 2020 Jan 23;10(1):1063.
- Marcu LG. Gender and sex-Related differences in Normal tissue effects induced by platinum compounds. Pharmaceuticals (Basel). 2022 Feb 20;15(2):255.
- Hellgren M, Conard J, Norris L, et al. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone. Maturitas. 2009 Mar 20;62(3):287–293.